These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15471508)

  • 1. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.
    Rahme E; Barkun AN; Adam V; Bardou M
    Drug Saf; 2004; 27(13):1019-42. PubMed ID: 15471508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study.
    Knijff-Dutmer EA; Postma MJ; van der Palen J; Brouwers JR; van de Laar MA
    Clin Ther; 2004 Jul; 26(7):1160-7. PubMed ID: 15336481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.
    Laine L; Wogen J; Yu H
    Gastroenterology; 2003 Aug; 125(2):389-95. PubMed ID: 12891540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
    Fendrick AM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs.
    Stockl K; Cyprien L; Chang EY
    J Manag Care Pharm; 2005 Sep; 11(7):550-8. PubMed ID: 16137212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy.
    Moore RA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():7-15; discussion 35-42. PubMed ID: 12173280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs.
    Pok LSL; Shabaruddin FH; Dahlui M; Sockalingam S; Mohamed Said MS; Rosman A; Lau IS; Isa LM; Hussein H; Ng CT; Mahadeva S
    Int J Rheum Dis; 2018 May; 21(5):943-951. PubMed ID: 29314744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
    Schaefer M; DeLattre M; Gao X; Stephens J; Botteman M; Morreale A
    Curr Med Res Opin; 2005 Jan; 21(1):47-60. PubMed ID: 15881475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.